Country Overview (Pharma & Healthcare)


Publication Single User License (PDF) Price
Latest Regulations on Pharmaceutical International Multi-Center Clinical Trials in China

Latest Regulations on Pharmaceutical International Multi-Center Clinical Trials in China

Date Published: Mar 20 2015
"China’s healthcare market is indispensable for overseas and multinational pharmaceutical companies, but Chinese regulations on pharmaceutical clinical trials are undergoing sharp changes. This is first time in history, Chinese pharmaceutical authorities officially issued a guidance on international multi-center clinical trials of drugs in China, which has begun to be implemented on March 1, 2015. To enter into Chinese lucrative drug market, the overseas and multinational pharmaceutical manufacturers must be compliance with this latest regulations.
$1,495.00
Vietnam Medical Devices Report Q2 2015

Vietnam Medical Devices Report Q2 2015

Date Published: Mar 18 2015
The Vietnamese medical device market is expected to remain one of the strongest in Asia, despite a moderation in import growth over the past couple of years. Continuing strong economic growth and increasing political/trade links with the outside world should boost income levels and allow for a continuation in the rapid rise in health spending seen in recent years. The country has attracted increasing interest from foreign investors and is starting to establish itself as a low-cost manufacturing base.
 
$1,295.00
Sudan and South Sudan Pharmaceuticals and Healthcare Report Q2 2015

Sudan and South Sudan Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Mar 18 2015
Access to healthcare in Sudan and South Sudan is poor and drug shortages are commonplace. The state is also heavily reliant on importing its medicines, though over the long-term we believe this reliance will decrease as the government is committed to developing domestic pharmaceutical production.
 

Headline Expenditure Projections 

$1,295.00
Colombia Medical Devices Report Q2 2015

Colombia Medical Devices Report Q2 2015

Date Published: Mar 18 2015
$1,295.00
Angola Pharmaceuticals and Healthcare Report Q2 2015

Angola Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Mar 18 2015
Due to its importance in the country's continued economic diversification and the government's focus on retaining political stability, government spending on healthcare in Angola will remain unaffected by any potential budget cuts resulting from declining oil prices.
 
$1,295.00
United Kingdom Pharmaceuticals and Healthcare Report Q2 2015

United Kingdom Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Mar 18 2015
The ageing population will have an unprecedented impact on the demand of healthcare and therapeutics in the UK. On the pharmaceutical front, the UK is a key international player, and will continue to be for the foreseeable future. However, the climate of cost containment, coupled with patent expirations, will lower the overall value of the UK's drug market.
 

Headline Expenditure Projections 

$1,295.00
Czech Republic Medical Devices Report Q2 2015

Czech Republic Medical Devices Report Q2 2015

Date Published: Mar 18 2015
The Czech medical device market is expected to grow by a CAGR of 8.4% over the 2013-2018 period, alongside increases in GDP, imports and health expenditure. The Czech Republic is heavily reliant on imported medical devices, although domestically manufactured products are of an increasingly good quality and remain competitive in terms of price.
 

Headline Industry Forecasts 

$1,295.00
Bahrain Pharmaceuticals and Healthcare Report Q2 2015

Bahrain Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Mar 18 2015
We uphold our view that Bahrain's pharmaceutical and healthcare sector will maintain strong and consistent growth over our forecast period. We believe that the country's ageing population will help drive medicine demand along with an increasing chronic disease burden and robust economic growth. However, continuing political tensions between the Sunni-dominated Khalifa regime and the Shi'a opposition threatens the country's stability, deterring foreign investors and limiting the pharmaceutical market's potential.
 
$1,295.00
United States Pharmaceuticals and Healthcare Report Q2 2015

United States Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Mar 18 2015
The US pharmaceutical market's status as the most lucrative globally is unassailable. This is due to unparalleled healthcare access, considerable spending power, a high burden of disease, minimal market access barriers and intense company activity. The key risks to this positive outlook are the increasing influence of pharmacy benefit managers and greater regulation, such as the Branded Prescription Drug Fee.
 

Headline Expenditure Projections 

$1,295.00
Hong Kong Medical Devices Report Q2 2015

Hong Kong Medical Devices Report Q2 2015

Date Published: Mar 18 2015
The Hong Kong medical device market has experienced strong growth in recent years and this is expected to continue over the forecast period, with the highest growth projected for the patient aids sector. Imports of medical devices to Hong Kong are high, especially for such a small market.
 
$1,295.00
Belarus Pharmaceuticals and Healthcare Report Q2 2015

Belarus Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Mar 18 2015
The volatility of the Belarusian rouble and high inflation will hurt consumer incomes and therefore the growth outlook of the pharmaceutical market over the next two years. Furthermore, increased scrutiny by President Lukashenko over pharmaceutical imports indicates that Belarus may follow neighbouring Russia in instituting measures that favour the domestic industry and restrict the market for pharmaceutical imports.
 

Headline Expenditure Projections

$1,295.00
Zimbabwe Pharmaceuticals and Healthcare Report Q2 2015

Zimbabwe Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Mar 18 2015
Zimbabwe's Treasury has failed to assign sufficient funds to the health sector in its 2015 National Budget, causing the country's healthcare system to continue to rely on funding from donor partners and developmental agencies. Political and economic uncertainty will continue to deter investment from multinational drug makers.
 
$1,295.00
India Medical Devices Report Q2 2015

India Medical Devices Report Q2 2015

Date Published: Mar 18 2015
$1,295.00
Cuba Pharmaceuticals and Healthcare Report Q2 2015

Cuba Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Mar 18 2015
The Cuban government's strong commitment to its pharmaceutical and healthcare sector, as shown through growing investment, will ensure the continued development of Cuba's healthcare market. Recent talks between Cuba and the US, increases to trade relations which boost Cuban medicine exports, and international medicine commercialisation deals all solidify Cuba's trajectory for further medical growth and innovation. Therefore, Cuba will continue to offer profitable opportunities to foreign investors.
 
$1,295.00
Kenya Medical Devices Report Q2 2015

Kenya Medical Devices Report Q2 2015

Date Published: Mar 18 2015
The Kenyan medical device market is expected to grow by a CAGR of 14.4% over the 2013-2018 period, alongside impressive GDP growth and strengthening imports. Almost all medical devices are imported, as domestic production is limited to basic consumable items, a situation that is expected to remain unchanged for the foreseeable future. Demand for medical devices remains high as many health facilities require modernisation.
 

Headline Industry Forecasts 

$1,295.00
Estonia Pharmaceuticals and Healthcare Report Q2 2015

Estonia Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Mar 18 2015
Positive consumer dynamics will drive growth in pharmaceutical sales in Estonia. We see an opportunity emerging as the Baltic countries of Lithuania, Latvia and Estonia jointly procure pharmaceuticals for their collective needs. Despite the small size of Estonia's pharmaceuticals industry, there is the potential for manufacturers to use the country as a low-cost export base, rather than focusing on the country's own market. The key risk continues to be tense Western-Russian relations.
 
$1,295.00
Norway Medical Devices Report Q2 2015

Norway Medical Devices Report Q2 2015

Date Published: Mar 18 2015
The Norwegian medical device market is limited by the size of the population, but enjoys above average per capita spending of USD294. The market is projected to grow at a US dollar CAGR of 3.1% to 2018 with the ageing population the main growth driver. The market will continue to be import-led with much of domestic production geared to the export market.
 

Headline Industry Forecasts 

$1,295.00
Finland Pharmaceuticals and Healthcare Report Q2 2015

Finland Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Mar 18 2015
Finland's pharmaceutical sector's growth is slowing, as is the case with many other mature western countries. The government is continually looking to new reforms and price control policies as it attempts to reduce spiralling healthcare costs associated with the country's aging population. Poor Economic performance continues to add downward pressure on our forecast. We expect pharmaceutical expenditure in Finland to grow by a local five-year compound annual growth rate of 2.2%.
 
$1,295.00
Oman Medical Devices Report Q2 2015

Oman Medical Devices Report Q2 2015

Date Published: Mar 18 2015
BMI estimates the Omani medical device market stood at USD111.6mn in 2013, equal to USD31.0 per capita. Imports account for the majority of the market, as domestic production is limited. The market as a whole is expected to grow at a healthy CAGR of 11.4% per annum to reach USD191.4mn by 2018.
 

Headline Industry Forecast 

$1,295.00
Philippines Pharmaceuticals and Healthcare Report Q2 2015

Philippines Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Mar 18 2015
The Philippine government will face growing headwinds in attracting innovative drugmakers to expand their operations in the country due to the rising domestic use of generic drugs and the logistical risks preventing companies from using it as a regional distribution hub. This will weigh on the overall attractiveness of the domestic market which we forecasted to grow steadily over the next five years at a compound annual growth rate of 4.5% in local currency terms.
 

Headline Expenditure Projections 

$1,295.00

Pages

Shopping cart

0 Items $0.00
Not able to find what you are looking for?
Call Us
WHY CHOOSE MARKET RESEARCH REPORTS?
1
Trusted By Leaders
2
Shop With Confidence
3
Customer Centric
4
Personalized Solutions
5
Secure Checkout

User login

Clients Who Trust Us

Orange, Google, Microsoft, Barclays, CassidianIntel, TPG, Elit Net, Cross Business Producers, AcmavolpakP&G, Cisco, Gemalto, General Insurance Corporation of India, Aviva, Cognizant, InoxWindB. Braun, Cobham, fiserv, Harris, Wipro, AonAl Meera, Nomura Research Institute, Tata Consultancy Services, Amara Raja, Hiranandani EnergyMunich Re, Lotte Chemical, National Post, First Data